|
| |
Aetiology
Drugs
- Antibiotics
- Additives eg sorbitol
- Pulmonary - theophylline
- GI
- magnesium antacids
- H2 blockers
- misoprostol
- sulfasalazine
- Anti-neoplastic agents
- Anti-arrhythmics
- quinidine
- procainamide
- digoxin
- Anti-hypertensives
- beta blockers
- ACE inhibitors
- hydralazine
- guanethidine
- diuretics
- Cholesterol medications
- lovastatin
- gemfibrozil
- probucol
- Thyroxine
Enteral nutrition
Accounts for only 20% of cases of diarrhoea in enterally fed patients in ICU.
Osmotic diarrhoea. Typically produces a stool with an osmotic gap of > 100
mOsm/kg. Thought to be the result of malabsorption, the cause of which is not
known. Possible that malabsorption is due to malnutrition, or antibiotic
therapy.
Catabolic state results in flattening of intestinal villi, crypt atrophy,
reduced levels of mucosal digestive proteins and decreased production of gut
hormones (eg gastrin, cholecystokinin). Also possible that mucosal changes
result from luminal nutritional deprivation rather than overall nutritional
state as the same changes occur in patients fed intravenously.
Impairment of colonic fermentation of carbohydrates possibly the most
important factor in antibiotic induced diarrhoea in enterally fed patients.
Unabsorbed carbohydrates are usually fermented by colonic bacteria to short
chain fatty acids. These are a major stimulus to sodium and water absorption in
the large intestine so the problem caused by the osmotic load of the unfermented
carbohydrates is compounded by decreased colonic salt and water absorption
Infections
- Clostridium difficile (see below)
- Salmonella, Shigella, Campylobacter and Yersinia (rare in ICU setting)
- E coli 0157:H7 serotype. May also be associated with haemolytic uraemic
syndrome or thrombotic thrombocytopaenic purpura
Miscellaneous
- any cause of diarrhoea eg faecal impaction, ischaemic bowel
Assessment
History
-
Duration and speed of onset
-
Stool characteristics: watery, bloody, mucous,
purulent, greasy etc
-
Frequency of bowel opening and quantity of stool
-
Symptoms of dysentery: fever, tenesmus, blood or
pus in stools
-
Symptoms of volume depletion: thirst, tachycardia,
postural faintness, decreased urination, lethargy
-
Associated symptoms: nausea, vomiting, abdominal
pain, cramps, headache, myalgia
-
Epidemiological risk factors:
-
Travel
-
Attendance or employment in day care facility
-
Consumption of unsafe foods eg raw meats, eggs,
shellfish, unpasteurized milk
-
Swimming in or drinking untreated fresh
surface water from, for example, a lake or stream
-
Contact with animals
-
Contact with patient with diarrhoea
-
Past medical history. Conditions which predispose
to infectious diarrhoea include:
-
AIDS
-
Immunosuppression
-
Gastrectomy
-
Medication
-
Sexual preferences
- Employment
as food handler or caregiver
Frequency of clinical features varies according to aetiological agent
although there is considerable overlap:
|
|
Fever
|
Abdo pain
|
Tenesmus
|
Bloody stool
|
Vomiting
and/or nausea
|
|
Salmonella
|
+++
|
++
|
-
|
+
|
++
|
|
Shigella
|
+++
|
+++
|
+++
|
++
|
+++
|
|
Campylobacter
|
+++
|
+++
|
-
|
+
|
++
|
|
STEC O157
|
+
|
+++
|
Rare
|
++
|
++
|
|
C.
difficile
|
+
|
+
|
-
|
-
|
-
|
|
Yersinia
|
++
|
++
|
|
+
|
++
|
|
Entamoeba
histolytica
|
+
|
|
|
|
|
|
Cryptosporidium
|
+++
|
+++
|
|
+
|
++
|
|
Cyclospora
|
++
|
+++
|
|
|
+
|
STEC = Shiga toxin producing E. coli
Examination
-
Signs of dehydration
-
Abdominal examination
-
Abdominal tenderness
-
Rectal examination
Investigations
-
Stool electrolytes. Calculate osmolar gap based on
assumption that stool osmolality is 290 mOsm/kg as measurement of stool
osmolality is difficult for technical reasons. Osmolar gap = 290 - 2(Na +
K). Gap > 100 mOsm/kg is indicative of osmotic diarrhoea which is most
likely to be due either to drugs or to malabsorption of enteral feed
-
If diarrhoea is osmotic and there is no drug which
is likely to be responsible try changing patient to peptide based diet
(peptides absorbed more effectively than amino acids during disease states
associated with impaired small bowel absorption). If diarrhoea persists stop
and consider changing to IV feeding. Little evidence that fibre supplements,
change in feed osmolarity, temperature or fat content or use of aseptic
technique is useful.
-
If diarrhoea is not osmotic then by far the most
likely cause is C. difficile colitis. Treatment of choice is enteral
vancomycin 125 mg qds. Metronidazole is an alternative in less seriously ill
patients
-
Routine examination of stool for enteric pathogens
is of low yield unless diarrhoea was present within 24-48 h of admission to
ICU
Suspected infectious diarrhoea
Treatment
Suspected infectious diarrhoea
Consider empirical treatment for:
-
Giardiasis in patients with diarrhoea that lasts
more than 10-14 days if other evaluations are negative and if the
patient’s history of travel or water exposure is suggestive
-
Patients with febrile diarrhoeal illnesses,
particularly those thought to have moderate or severe invasive disease.
Quinolones are drugs of choice although Campylobacter and Salmonella
resistance to quinolones is increasing
-
Shiga toxin-producing E. coli (STEC)
infections
-
Avoid anti-motility agents
-
Treatment of STEC O157 infections with
antimicrobial agents does not ameliorate the diarrhoea and may increase the
risk of developing haemolytic uraemic syndrome
|
Pathogen
|
Recommendations
|
|
Shigella
|
Co-trimoxazole
960 mg bd (if susceptible) or fluoroquinolone for 3 d (7-10 d in
immunocompromised), or ceftriaxone or azithromycin
|
| Salmonella
(non-typhi)
|
Routine
treatment not recommended. If sever or patient < 6 months or >50 yrs
or has prosthesis, valvular heart disease, severe atherosclerosis,
malignancy or uraemia: cotrimoxazole 960 mg bd (if susceptible) or
fluoroquinolone for 5-7 d or ceftriaxone 100 mg/kg/day
|
|
Campylobacter
|
|
|
E.
coli
Enterotoxigenic
Enteropathogenic
Enteroinvasive
Enteroaggregative
|
Cotrimoxazole
960 mg bd (if susceptible)
or fluoroquinolone
for 3 days
Consider
fluoroquinolone for 3 d in immunocompromised patients
|
| Aeromonas
or Plesiomonas
|
|
|
Yersinia
|
For
severe infections or associated bacteraemia: cotrimoxazole,
fluoroquinolone or doxycycline plus aminoglycoside
|
| Vibrio
cholerae O1 or O139
|
Doxycycline
300 mg single dose or tetracycline 500 mg 6 hrly for 3 days or
cotrimoxazole 960 mg for 3 days or single dose fluoroquinolone
|
|
Giardia
|
Metronidazole
250-750 mg 8 hrly for 7-10 days
|
|
Cryptosporidium
|
Severe
cases: paromomycin 500 mg 8hrly for 7 days
Immunocompromised: paromomycin 500 mg 8hrly for 14-28 d then 12hrly if
needed. Highly active anti-retroviral therapy including a protease
inhibitor is warranted for patients with AIDS
|
|
Isospora
|
Cotrimoxazole
960 mg bd for 7-10 days (6 hrly for 10 days followed by thrice weekly or
weekly sulfadoxine 500 mg and pyrimethamine 25 mg indefinitely for
patients with AIDS)
|
|
Cyclospora
|
Cotrimoxazole
960 mg bd for 7 days (6 hrly for 10 days followed by thrice weekly
indefinitely for patients with AIDS)
|
|
Microsporidium
|
Immunocompromised:
albendazole 400 mg bd for 3 weeks. Highly active anti-retroviral therapy
including a protease inhibitor is warranted for patients with AIDS
|
|
Entaemoeba
histolytica
|
Metronidazole
759 mg 8 hrly for 5-10 days plus either diiodohydroxyquin 650 mg 8 hrly
for 20 days or paromomycin 500 mg 8 hrly for 7 days
|
|